Specific to patients with muscle invasive bladder cancer, improvement in disease free survival was also observed with ...

First-line treatment with disitamab vedotin and toripalimab improved outcomes over chemotherapy in patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma.

Loqtorzi significantly improved progression-free and overall survival in HER2-expressing advanced urothelial carcinoma compared to chemotherapy. The study demonstrated a higher overall response rate ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

HER-2 targeted antibody-drug conjugate monotherapy has demonstrated efficacy in the post-chemotherapy setting for ...

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...

The median duration of response was 9.2 months. The combination of atezolizumab and split doses of cisplatin and gemcitabine can produce durable responses in patients with locally advanced or ...

Over the past decade, immunotherapy has fundamentally reshaped the therapeutic landscape for several urological cancers, this mostly involved urothelial ...

Initial results from one sub-study of the TROPION-PanTumor03 phase 2 trial showed that DATROWAY® (datopotamab deruxtecan) plus rilvegostomig showed promising tumor responses and disease control as ...

The study not only enhances survival prediction but also provides novel evidence for a causal genetic link between prostate cancer and urothelial carcinoma. The team analyzed records of 6,363 prostate ...